演題
|
PH13-3
胃癌における血小板数と血清Fibrinogenの臨床的意義:腫瘍進行度や予後の予測に有用な凝固系スコア―の検討 |
Background: Some patients with early gastric cancer die of recurrent disease and cancer-related complications. Difficulties are associated with clinically predicting tumor progression and prognosis based on conventional tumor markers determined from preoperative blood examinations.
Objective: To investigate platelet count, plasma fibrinogen concentrations, and prothrombin activity in blood specimens from patients with gastric cancer and assess the clinical impact of combining platelet count with fibrinogen (CBS: coagulation blood score) as a prognostic marker.
Methods: We classified 275 patients with gastric cancer based on cut-off values for elevated platelet count ³295,000/mm3 and hyperfibrinogenemia ³305 mg/dL as CBS of 2 (both hematological abnormalities), 1 (one of these abnormalities) or 0 (neither abnormality).
Results: Platelet count, fibrinogen, and prothrombin activity correlated with the depth of tumor invasion, the presence or absence of lymph node metastasis, and stage (all P<0.05). The univariate analysis demonstrated platelet count and fibrinogen as prognostic factors (all P<0.05). According to the criteria of CBS, 101 (36.9%), 134 (48.9%), and 39 (14.2%) patients had CBS of 0, 1, and 2, respectively. CBS significantly correlated with the depth of tumor invasion, lymph node metastasis, and stage (all P<0.05). Prognostic differences among the groups were significant (P<0.01).
Conclusions: CBS is a potentially useful blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
Objective: To investigate platelet count, plasma fibrinogen concentrations, and prothrombin activity in blood specimens from patients with gastric cancer and assess the clinical impact of combining platelet count with fibrinogen (CBS: coagulation blood score) as a prognostic marker.
Methods: We classified 275 patients with gastric cancer based on cut-off values for elevated platelet count ³295,000/mm3 and hyperfibrinogenemia ³305 mg/dL as CBS of 2 (both hematological abnormalities), 1 (one of these abnormalities) or 0 (neither abnormality).
Results: Platelet count, fibrinogen, and prothrombin activity correlated with the depth of tumor invasion, the presence or absence of lymph node metastasis, and stage (all P<0.05). The univariate analysis demonstrated platelet count and fibrinogen as prognostic factors (all P<0.05). According to the criteria of CBS, 101 (36.9%), 134 (48.9%), and 39 (14.2%) patients had CBS of 0, 1, and 2, respectively. CBS significantly correlated with the depth of tumor invasion, lymph node metastasis, and stage (all P<0.05). Prognostic differences among the groups were significant (P<0.01).
Conclusions: CBS is a potentially useful blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
